Fatty liver disease (MASLD/MASH)
A common condition in which fat builds up in the liver, often linked to carrying extra weight.1 Most people have no signs, and it is often found by chance during tests for something else.1 Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage.1 It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.2
Read more about Fatty liver disease (MASLD/MASH)Trial-stage treatments and research studies you can join
Filters
- Tests efruxifermin in adults with cirrhosis caused by fatty liver disease
Tests efruxifermin against a placebo in adults with cirrhosis from MASH.
Akron, United StatesAlso Amarillo, Arlington, Atlanta, Aurora, Austin, Baltimore, Bastrop, Bellaire, …Age 18 to 80 - Two experimental drugs, alone and together, for fatty liver disease with inflammation (MASH)
Tests ECC4703 and ECC0509, alone and combined, in adults with presumed MASH.
Akron, United StatesAlso Apple Valley, Austin, Bellaire, Bradenton, Brownsville, Chandler, Columbia, Cordova, …Age 18 to 75 - Testing ALN-CIDEB for fatty liver disease with liver scarring in adults
Tests the study drug ALN-CIDEB against placebo in adults with liver scarring from MASH.
Arlington, United StatesAlso Austin, Dallas, Danville, Doral, Fort Myers, Georgetown, Houston, Indianapolis, …Age 18 to 75 - Tests efruxifermin in adults with liver scarring from fatty liver disease
Tests efruxifermin against a placebo in adults with fatty liver disease and mild liver scarring.
Amarillo, United StatesAlso Atlanta, Aurora, Austin, Baltimore, Bastrop, Bellaire, Birmingham, Bradenton, …Age 18 to 80 - Tests efimosfermin alfa in people with cirrhosis caused by fatty liver disease
Tests efimosfermin alfa against placebo in adults with early cirrhosis from MASH.
Austin, United StatesAlso Baltimore, Chandler, Dallas, Fayetteville, Fresno, Georgetown, Houston, Kansas City, …Age 18 to 75 - Efimosfermin alfa in adults with liver impairment from fatty liver disease
Tests how the body handles efimosfermin alfa in adults with fatty liver disease.
Houston, United StatesAlso Miami Lakes, Rialto, San Antonio, TampaAge 18 to 70 - Tests efimosfermin against placebo in adults with cirrhosis from MASH
Tests efimosfermin alfa against placebo in adults with cirrhosis caused by MASH.
Arlington, United StatesAlso Austin, Bellaire, Cape Coral, Dallas, Folsom, Fort Myers, Hialeah, Homestead, …Age 18 to 75 - Testing efimosfermin against placebo in adults with cirrhosis from MASH
Tests efimosfermin, compared with placebo, in adults with cirrhosis caused by MASH.
Arcadia, United StatesAlso Arlington, Arroyo Grande, Austin, Bellaire, Cape Coral, Dallas, East Syracuse, Folsom, …Age 18 to 75 - Testing ALN-CIDEB against placebo in adults with fatty liver disease linked to metabolic problems
Tests whether ALN-CIDEB helps treat a liver disease caused by fat build-up in adults.
Georgetown, United StatesAlso Marrero, Metairie, MiamiAge 18 to 75 - Survodutide and heart structure and function in people with obesity and fatty liver disease
Tests survodutide against placebo on heart health in adults with overweight and fatty liver.
Albuquerque, United StatesAlso Boston, Bristol, Dallas, Durham, Kansas City, Los Angeles, Oxnard, Pasadena, …Age 18+ - Tests survodutide in adults with liver disease and moderate or advanced liver fibrosis
Tests survodutide weekly injections against placebo in adults with fatty liver disease and scarring.
Altamonte Springs, United StatesAlso Arlington, Austin, Baltimore, Bastrop, Bellaire, Birmingham, Boston, Bradenton, …Age 18+ - Tests survodutide in adults with liver scarring from fatty liver disease
Tests survodutide, a weekly injection, in adults with MASH cirrhosis.
Arlington, United StatesAlso Atlanta, Austin, Bastrop, Bellaire, Bradenton, Brandon, Bristol, Brooklyn, …Age 18+ - Tests semaglutide in adults with fatty liver disease and healthy volunteers
Studies how the liver responds to feeding and to semaglutide in adults.
Bethesda, United StatesAge 18 to 100 - Tests pegozafermin against placebo in liver scarring from fatty liver disease
Tests pegozafermin doses versus placebo in adults with MASH and liver scarring.
Akron, United StatesAlso Albany, Albuquerque, Amarillo, Athens, Austin, Baltimore, Bellaire, Bellevue, …Age 18 to 80 - Tests pegozafermin in adults with liver scarring from fatty liver disease
Tests pegozafermin against placebo in adults with compensated cirrhosis from MASH.
Akron, United StatesAlso Albany, Albuquerque, Amarillo, Ann Arbor, Asheville, Athens, Atlanta, Austin, …Age 18 to 75 - Tests a liver pressure procedure with stomach surgery in adults with cirrhosis and obesity
Compares a liver pressure procedure plus stomach surgery with weight care in adults with cirrhosis.
Cleveland, United StatesAge 18 to 70 - Resmetirom in adults with fatty liver disease MASH and heart failure
Tests resmetirom against placebo in adults with MASH and HFpEF.
Fort Myers, United StatesAlso Oxnard, Peoria, Riverview, University ParkAge 18+ - Rezdiffra taken together with diabetes medicines in adults with MASH liver scarring
Tests Rezdiffra with diabetes drugs in adults with MASH and liver fibrosis.
Arlington, United StatesAlso Chandler, Chattanooga, Cincinnati, Coronado, Corpus Christi, Dallas, Lake Charles, Lakewood Rch, …Age 18+ - Tests BI 3802876 Tolerability in People With Cirrhosis From MASH
Tests how well BI 3802876 is tolerated in adults with cirrhosis due to MASH.
Arlington, United StatesAlso Baltimore, Carrollton, Chandler, Charleston, Colorado Springs, Columbus, Coronado, Dallas, …Age 18 to 75 - Tests retatrutide and tirzepatide in adults with fatty liver disease at high risk
Tests retatrutide and tirzepatide in adults with fatty liver disease to prevent serious liver problems.
Akron, United StatesAlso Albuquerque, Aurora, Austin, Baltimore, Bastrop, Beavercreek, Bellaire, Bellevue, …Age 18+
Where treatment stands
These texts do not say it can be cured, but healthy lifestyle changes can reduce fat in the liver, help repair damage or stop it getting worse.
Where research stands now
On 11 November 2026, 425 trials and studies of fatty liver disease were open. On that day, 127 treatments were being tested in people; 25 reached phase 3, the last large trials before approval. Between 5 November 2025 and 11 November 2026, articles described 126 treatment studies in people, 741 in animals and 55 in cells. Recent EU-listed medicines are resmetirom (first EU approval August 2025) and semaglutide (March 2026), maybe first for another disease. Health pages say more studies must show whether certain medicines are safe and work well.
We found 2 medicines approved for fatty liver disease (MASLD / MASH) in the EU, the US, Switzerland or France, and 18 being tested in people.
Approved: 2
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 18
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 5
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 1
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The trials: ClinicalTrials.gov and the EU trials register, as copied into our trial database, checked on 12 November 2026. Every treatment in trials links to its own trial records; the texts are written by AI from them and checked against them by a second AI. People have not reviewed them yet. Placebo, standard medicines used for comparison and procedures are left out.
Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 53 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for fatty liver disease (MASLD / MASH). AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
Support organisations
Patient organisations and helplines in United States, for you and your family.
Fatty liver disease (MASLD/MASH) organisations in United States
- Fatty Liver Foundation
US patient-focused nonprofit raising awareness of fatty liver disease (NAFLD/NASH) and cirrhosis, with education and support for patients.
General support in United States
- 988 Suicide & Crisis Lifeline
US national 24/7 free and confidential lifeline for anyone in suicidal crisis or emotional distress, reachable by calling or texting 988 or by chat.
- MedlinePlus
Free, easy-to-read health information service of the US National Library of Medicine (NIH) on diseases, conditions, drugs and wellness.
International organisations
Offer tissue or data
There are three ways to help research move faster.
Treatments approved outside the EU
We found no medicine for Fatty liver disease (MASLD/MASH) approved in the US or Japan that is not approved in the EU. These are the ones approved in the EU.
Checked on 11 Nov 2026 in the official lists of the US (FDA), Japan (PMDA, approvals since April 2004) and the EU (EMA).
Your health insurer may pay part of the cost, sometimes all of it. This depends on your insurer, your plan and the country, so always ask your insurer before you go. For planned care in the EU, the EEA and Switzerland, ask about form S2.
“Miracle cure” fact checker
Social media spreads misinformation. Paste what you read here, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- Omega-3 fatty acids (fish oil) & Fatty liver disease (MASLD/MASH)
- Curcumin (turmeric) & Fatty liver disease (MASLD/MASH)
- Stem cell treatment & Fatty liver disease (MASLD/MASH)
- CBD (cannabidiol) & Fatty liver disease (MASLD/MASH)
About Fatty liver disease (MASLD/MASH)
A common condition in which fat builds up in the liver, often linked to carrying extra weight.1 Most people have no signs, and it is often found by chance during tests for something else.1 Losing weight, eating well and exercising can cut the fat in the liver and may repair some damage.1 It is more common in people with type 2 diabetes, obesity or high blood pressure, and in middle-aged and older adults.2
What is it?
In this condition fat builds up in the liver.1 Its new name is MASLD (metabolic dysfunction-associated steatotic liver disease); it used to be called NAFLD.1,2 It is not caused by heavy drinking.2 There are four stages: fat alone (most people only have this and it does not usually cause problems); fat with inflammation (MASH, once called NASH); fibrosis (scarring); and cirrhosis, severe damage that affects how well the liver works.1,2
It is very common: it is the most common long-term liver disease.2,1 It is more likely if you are overweight, especially around the waist, if you have type 2 diabetes, high blood pressure or high cholesterol, if you are not very active, or if you are over 50.1 Children can get it too.2 The exact cause is not known.2
The first signs
Usually there are no signs, and it is often found during tests for something else.1
How doctors find out
It is usually found after blood tests or scans done for another reason show signs of problems with your liver.1,2 Your family doctor asks about your symptoms and how much alcohol you drink, and measures your height, weight and waist.1 More blood tests and sometimes an ultrasound scan of your tummy can show the fat, rule out other causes and check for liver damage.1 If there is damage to your liver, you will need to see a liver specialist in hospital. Sometimes a biopsy is done to confirm the diagnosis and check for liver damage.1,2
Current treatment
Lifestyle changes for everyone (healthy diet, at least 150 minutes of exercise a week, weight loss, little alcohol, no smoking), with pioglitazone or vitamin E from a specialist if there is scarring.Source: NHS
Will it get worse?
Most people only ever have the first stage, which usually causes no problems.1 A small number go on to inflammation and scarring, and some to cirrhosis, which can lead to bleeding inside the body, liver failure or liver cancer.1,2 It is also linked to heart disease, kidney disease, high blood pressure and type 2 diabetes.1 Healthy changes lower all these risks.1
Medicines: what helps, and what to watch for
If there is scarring, a liver specialist may prescribe pioglitazone or vitamin E.1 For people with obesity, specialists may suggest weight-loss medicines.1 More research is needed to know which medicines are safe and work well.2
Healthy changes help most
Weight-loss surgery or a transplant, for some people
For people with obesity, a specialist may recommend weight-loss surgery.1 In very severe cases, when the liver fails, a liver transplant may be needed.1,2
Can it get better?
Healthy changes can reduce the fat in the liver and may repair damage or stop it getting worse.1 More studies are needed to see whether certain medicines are safe and work well to treat MASLD; studies are listed on ClinicalTrials.gov.2
Sources
Written in plain words by Frontlight from these pages: